Vamifeport (VIT-2763) is a novel orally active inhibitor that targets iron transport proteins and reduces markers of hemolysis in the SCD Townes model.VIT-2763 improves anemia and erythropoiesis, ameliorates vascular inflammation, and can be studied in β-thalassemia.

Ferroportin-IN-1 is an inhibitor of the iron transport protein Ferroportin, which regulates cellular iron efflux and metabolism to study diseases caused by iron-modulating deficiencies or disorders of iron metabolism, used in metabolism studies such as thalassemia, sickle cell disease, and hemochromatosis.

Fursultiamine (Alinamin F) is a disulfide derivative of thiamine, or an allithiamine. It has potential uses in the treatment of vitamin B1 deficiency.

Hepcidin antagonist-1 is an iron-modulating antagonist.Hepcidin antagonist-1 can be used to study metabolic disorders such as iron-deficiency diseases and anemia.

DMT1 blocker 1 is a blocker of divalent metal transporter 1 (DMT1) with IC50 of 0.64 μM, which is expected to block the absorption of iron by intestinal cells in vivo.

DMT1 blocker 2, compound 12f, is a direct inhibitor of divalent metal transporter 1 (DMT1) with an IC50 hydrogen peroxide value of 0.83, which is expected to block iron uptake by intestinal epithelial cells in vivo.

LY2928057 is a humanized antibody targeting the iron transporter SLC40A1 and acts as an iron regulator inhibitor, making it suitable for research into cardiovascular diseases. By blocking iron regulator binding and stabilizing the cell surface iron transporter, LY2928057 promotes iron release and utilization, making it applicable to research on anemia-related conditions such as chronic inflammatory anemia.

Pyrimidinone 8 is a reversible, linear non-competitive inhibitor of divalent metal transporter 1 (DMT1) with a Ki of 20 μM (hDMT1). It does not affect the surface expression of hDMT1 and is not influenced by extracellular pH. Pyrimidinone 8 inhibits hDMT1-mediated iron uptake, with an IC50 of 13.8 μM.

Anti-Hepcidin/HAMP Antibody is a human-derived antibody produced in CHO cells, targeting Hepcidin/HAMP. It features a huIgG1 heavy chain and a huλ light chain, with a predicted molecular weight (MW) of 145 kDa. The isotype control for this antibody can be referenced as HumanIgG1kappa, Isotype Control.

Anti-SLC40A1 Antibody is a human-derived antibody expressed in CHO cells, targeting SLC40A1, with a predicted molecular weight (MW) of 150 kDa.

Rusfertide, a peptide mimetic of natural hepcidin, targets and degrades ferroportin, thereby reducing serum iron and transferrin saturation, which helps regulate red blood cell production. It ameliorates conditions such as polycythemia vera, β-thalassemia, and hereditary hemochromatosis [1] [2].

DS28120313 is an oral inhibitor of hepcidin production (IC50: 0.093 μM).